Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 3,877 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Joseph Douglas Lyon sold 3,877 shares of the company's stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $73.48, for a total transaction of $284,881.96. Following the completion of the transaction, the insider directly owned 10,066 shares in the company, valued at $739,649.68. The trade was a 27.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Joseph Douglas Lyon also recently made the following trade(s):

• On Friday, July 18th, Joseph Douglas Lyon sold 200 shares of Corcept Therapeutics stock. The stock was sold at an average price of $73.40, for a total transaction of $14,680.00.
• On Tuesday, July 1st, Joseph Douglas Lyon sold 100 shares of Corcept Therapeutics stock. The stock was sold at an average price of $73.50, for a total transaction of $7,350.00.
• On Monday, June 2nd, Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $78.04, for a total transaction of $390,200.00.

Corcept Therapeutics Stock Performance

Corcept Therapeutics stock traded down $0.77 during midday trading on Wednesday, reaching $68.31. The company's stock had a trading volume of 361,996 shares, compared to its average volume of 1,181,745. Corcept Therapeutics Incorporated has a fifty-two week low of $32.33 and a fifty-two week high of $117.33. The stock's 50 day simple moving average is $72.68 and its 200 day simple moving average is $67.50. The firm has a market capitalization of $7.24 billion, a PE ratio of 58.96 and a beta of 0.15.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its earnings results on Monday, May 5th. The biotechnology company reported $0.17 EPS for the quarter, meeting analysts' consensus estimates of $0.17. The company had revenue of $157.21 million during the quarter, compared to the consensus estimate of $177.93 million. Corcept Therapeutics had a return on equity of 20.40% and a net margin of 19.33%. Corcept Therapeutics's quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.25 earnings per share. Equities analysts predict that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Canada Pension Plan Investment Board acquired a new position in shares of Corcept Therapeutics during the 4th quarter worth $40,000. National Bank of Canada FI acquired a new position in Corcept Therapeutics in the 4th quarter valued at about $42,000. Brooklyn Investment Group raised its stake in Corcept Therapeutics by 99.5% in the 1st quarter. Brooklyn Investment Group now owns 373 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 186 shares during the last quarter. USA Financial Formulas acquired a new position in Corcept Therapeutics in the 2nd quarter valued at about $56,000. Finally, Gen Wealth Partners Inc acquired a new position in Corcept Therapeutics in the 4th quarter valued at about $67,000. Institutional investors and hedge funds own 93.61% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Canaccord Genuity Group upped their target price on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st. Wall Street Zen lowered shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, May 14th. Piper Sandler increased their price target on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a research note on Thursday, April 3rd. Truist Financial set a $135.00 price target on shares of Corcept Therapeutics in a research note on Tuesday, May 6th. Finally, HC Wainwright decreased their price objective on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $138.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.